Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Abstract Background Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expressing programmed death ligand 1 (PD-L1). Methods Patients with advanced...

Full description

Bibliographic Details
Main Authors:	Janice M. Mehnert, Andrea Varga, Marcia S. Brose, Rahul R. Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha-Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam
Format:	Article
Language:	English
Published:	BMC 2019-03-01
Series:	BMC Cancer
Subjects:	Thyroid cancer Immunotherapy Pembrolizumab Anti–PD-1 PD-1 PD-L1
Online Access:	http://link.springer.com/article/10.1186/s12885-019-5380-3

Similar Items

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
by: Takuma Isshiki, et al.
Published: (2018-10-01)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
by: Nicolas A. Giraldo, et al.
Published: (2018-10-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
by: Yaxiong Zhang, et al.
Published: (2018-12-01)

The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report
by: Lyu M, et al.
Published: (2020-05-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Pulmonary large cell carcinoma, highly positive for PD‐L1, shows marked response to pembrolizumab: A case report
by: Naoyuki Okabe, et al.
Published: (2021-04-01)

Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report
by: Ali McBride, et al.
Published: (2021-07-01)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
by: Shifaa M. Abdin, et al.
Published: (2018-01-01)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
by: Elizabeth Dudnik, et al.
Published: (2021-01-01)

Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report
by: Kohichi Takada, et al.
Published: (2019-12-01)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
by: Sugano T, et al.
Published: (2018-09-01)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
by: Ning Wan, et al.
Published: (2020-03-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2017-06-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
by: Zhuang Y, et al.
Published: (2020-01-01)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
by: Qu J, et al.
Published: (2020-07-01)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2019-10-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
by: Xiong F, et al.
Published: (2020-07-01)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
by: Xin Li, et al.
Published: (2018-01-01)

Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
by: Yannick Verhoeven, et al.
Published: (2021-02-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
by: Eun-Ji Lee, et al.
Published: (2021-09-01)

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
by: Wagner LM, et al.
Published: (2017-04-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report
by: Alfonso Fiorelli, et al.
Published: (2019-03-01)

mRNA EXPRESSION OF PD-1, PD-L1, AND IMMUNOTHERAPY IN BLADDER CANCER
by: Muhammad Puteh Mauny, et al.
Published: (2021-07-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
by: Gang Liu, et al.
Published: (2021-08-01)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
by: Liudmila Spirina, et al.
Published: (2021-09-01)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
by: Jing W, et al.
Published: (2016-01-01)

Pembrolizumab‐induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient
by: Anthony D. Honigman, et al.
Published: (2019-04-01)

Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B
by: Wenjin Zhang, et al.
Published: (2012-08-01)

Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis
by: Akio Osa, et al.
Published: (2019-11-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report
by: Kazumi Nishino, et al.
Published: (2020-04-01)

Cannot write session to /tmp/vufind_sessions/sess_pefnrccocbg8ibm032rndr44t0